Investigators & KOL Network

Key investigators, leadership, and opinion leader network driving the Mays Cancer Center oncology portfolio.

Key Leaders

KOL Personas

Therapeutic Areas

Leadership

Core leadership driving the oncology portfolio

Dr. Daruka Mahadevan

Director, Investigational Drug Development

Chief, Hematology-Oncology

UT Health San Antonio / Mays Cancer Center

Molecules

DT2216Sacituzumab GBMBSI-082Pluvicto

Expertise

Investigational drug developmentHematologic malignanciesEarly-phase clinical trials

Dr. Daohong Zhou

Co-Director, CIDD

DT2216 Inventor

UT Health San Antonio

Molecules

DT2216

Expertise

PROTAC technologyBCL-XL biologySenolytic therapyDrug discovery

Dr. Stanton McHardy

Co-Director, CIDD

Drug Discovery Lead

UT Health San Antonio

Molecules

DT2216

Expertise

Medicinal chemistryDrug designPROTAC optimizationChemical biology

Dr. William Kelly

Principal Investigator

Sacituzumab GBM PI

Mays Cancer Center

Molecules

Sacituzumab GBM

Expertise

Neuro-oncologyGlioblastomaADC therapiesCNS clinical trials

Dr. John Sarantopoulos

Principal Investigator

BSI-082 PI

Mays Cancer Center

Molecules

BSI-082

Expertise

Phase 1 clinical trialsImmuno-oncologyFirst-in-human studiesDose escalation

Dr. Hong-yu Li

Research Faculty

Chemical Endocytic Breakthrough

UT Health San Antonio

Expertise

Chemical endocytosisDrug deliveryCell biologyPublished in Cell (2025)

Investigator Network

Cross-molecule investigator connections

DT2216

Dr. Daruka Mahadevan

Dr. Daohong Zhou

Dr. Stanton McHardy

Sacituzumab GBM

Dr. Daruka Mahadevan

Dr. William Kelly

BSI-082

Dr. Daruka Mahadevan

Dr. John Sarantopoulos

Pluvicto

Dr. Daruka Mahadevan

KOL Directory

Simulated key opinion leader personas across all molecules

Dr. Daohong Zhou

UT Health San Antonio

high

dt2216

Advancing PROTAC platform scienceSecuring continued CPRIT and NCI fundingExpanding indications based on preclinical data

Style: Academic

Dr. Daruka Mahadevan

UT Health San Antonio

high

dt2216

Patient safety and optimal dosingEfficient trial enrollment and executionDemonstrating clinical benefit vs standard of care

Style: Data-driven

Community Oncologist — T-cell Lymphoma

Community Practice

medium

dt2216

Practical treatment options for relapsed CTCL/PTCL patientsManageable toxicity profile for outpatient administrationClear biomarker guidance for patient selection

Style: Pragmatic

Dr. William Kelly

UT Health San Antonio

high

sacituzumab-gbm

Improving survival in recurrent GBM beyond current 6–9 month medianValidating Trop-2 as an actionable biomarker in GBMDemonstrating BBB penetration of ADCs in CNS tumors

Style: Data-driven

Academic Neuro-Oncologist

NCI-Designated Cancer Center

high

sacituzumab-gbm

Evidence-based treatment selection for rGBMMolecular subtyping to guide therapyParticipation in cooperative group trials

Style: Academic

Dr. John Sarantopoulos

UT Health San Antonio

high

bsi-082

Safe dose escalation with optimal SIRPα receptor occupancyDemonstrating anti-SIRPα is differentiated from failed anti-CD47 programsEnrolling first patient on time (Feb 2026)

Style: Data-driven

Immuno-Oncology Expert

NCI-Designated Cancer Center

high

bsi-082

Rigorous scientific evidence for innate immune checkpoint mechanismsUnderstanding why anti-CD47 failed and whether anti-SIRPα addresses root causesBiomarker-driven patient selection for innate immune approaches

Style: Academic

Nuclear Medicine Physician / Authorized User

Mays Cancer Center

high

pluvicto

Ensuring safe Pluvicto administration with proper dosimetryExpanding RLT access across South TexasTraining next generation of theranostics specialists

Style: Data-driven

Medical Oncologist — GU Oncology

Academic Medical Center

high

pluvicto

Optimal treatment sequencing in mCRPC (ARPI → chemo → RLT or ARPI → RLT → chemo)Patient access to Pluvicto without long wait timesUnderstanding PSMAfore implications for earlier use

Style: Pragmatic